Chronic kidney disease (CKD) is a known complication of the human immunodeficiency virus (HIV) but outcomes among HIV-infected patients with kidney disease are unknown. We studied a national sample of 202 927 patients with CKD (stage 3 or higher) for death, end-stage renal disease (ESRD) and the mean annual rate of decline in estimated glomerular filtration rate (eGFR) over a median period of 3.8 years. Within this sample, 0.3% of the patients were diagnosed with HIV, 43.5% were diabetic, whereas the remainder had neither disease. In this national CKD cohort, HIV-infected black patients were at higher risk of death, a similar risk for ESRD and loss of eGFR than black patients with diabetes. HIV-infected white patients experienced higher rates of death but a lower risk of ESRD than their counterparts with diabetes. Our results highlight a need to study mortality and mechanisms of ESRD in the HIV infected population.
Chronic kidney disease (CKD) is a known complication of the human immunodeficiency virus (HIV) but outcomes among HIV-infected patients with kidney disease are unknown. We studied a national sample of 202 927 patients with CKD (stage 3 or higher) for death, end-stage renal disease (ESRD) and the mean annual rate of decline in estimated glomerular filtration rate (eGFR) over a median period of 3.8 years. Within this sample, 0.3% of the patients were diagnosed with HIV, 43.5% were diabetic, whereas the remainder had neither disease. In this national CKD cohort, HIV-infected black patients were at higher risk of death, a similar risk for ESRD and loss of eGFR than black patients with diabetes. HIV-infected white patients experienced higher rates of death but a lower risk of ESRD than their counterparts with diabetes. Our results highlight a need to study mortality and mechanisms of ESRD in the HIV infected population. Although highly active antiretroviral therapy has resulted in dramatic improvements in morbidity related to the human immunodeficiency virus (HIV), many contemporary studies indicate that kidney disease is an increasingly frequent complication of HIV infection. 1, 2 In the United States, the prevalence of end-stage renal disease (ESRD) caused by HIVassociated nephropathy doubled between 1995 and 2000 and proteinuria may be present in up to 30% of HIV-infected individuals. 1, 3, 4 Kidney disease is also an important predictor of mortality among patients with HIV. Between 1995 and 1999, the proportion of death certificates listing kidney disease as an underlying cause increased from 6 to 9% among HIV-infected individuals nationally. 5 Prior work has demonstrated that elevated serum creatinine and proteinuria together or independently predict mortality among patients with HIV. 3, [5] [6] [7] [8] [9] [10] [11] However, relatively few studies have examined clinical outcomes among representative samples of patients with HIV and chronic kidney disease (CKD). Previous studies of outcomes in HIVinfected patients with renal disease were conducted among cohorts undergoing kidney biopsy 3, [6] [7] [8] [9] and women, 10,11 and thus may not be generalizable to the wider population of patients with HIV and CKD. To date, no studies have examined the incidence of ESRD, death, and loss of kidney function in large population of HIV-infected individuals with established CKD. The objective of this study was to characterize rates of death, ESRD, and kidney function decline among HIV-infected individuals in a national contemporary cohort of patients with CKD and compare them to rates among individuals with diabetes.
RESULTS
Among the 202 927 patients included in this study, 534 (0.3%) had HIV, 88 340 (43.5%) had diabetes, and 114 223 (56.3%) did not have either condition (Table 1) . Patients with HIV were younger (55.9 years710.1) than patients with diabetes (73.1 years78.8) or patients without HIV or diabetes (73.6 years79.0). Among patients with HIV, 50.4% (n ¼ 269) were black, whereas only 13.1% (n ¼ 11 575) of those with diabetes and 9.2% (n ¼ 10 531) of patients without either condition were black. The prevalence of severe CKD (estimated glomerular filtration rate (eGFR) 15-29 ml/min/1.73 m 2 ) and renal failure (eGFRo15 ml/min/1.73 m 2 ) was higher among patients with HIV (18.0%) compared with patients with diabetes (13.1%) and those without either condition (8.0%). Cardiovascular diseases were common in all groups, but were most prevalent in patients with diabetes. Hepatitis C virus coinfection was found in 27.3% (n ¼ 146) of HIV-infected patients, whereas only 1.3% (n ¼ 1182) of patients with diabetes and 1.0% (n ¼ 1144) of patients without either condition had hepatitis C virus. A higher percentage of patients with HIV (43.6%, n ¼ 233) were in the lowest tertile of socioeconomic status compared with patients with diabetes (35.7%, n ¼ 31 474) or patients without HIV or diabetes (33.6%, n ¼ 38 339). Among HIV-infected individuals, rates of treatment with highly active antiretroviral therapy at the time of cohort entry were comparable between white (20.4%) and black (17.5%) patients (P ¼ 0.461). Mean CD4 þ T-cell counts and HIV RNA levels were also similar between white and black patients at baseline (328 versus 305 cells/mm 3 , P ¼ 0.412, and 2.86 versus 3.15 log copies/ml, P ¼ 0.297, respectively).
The median observation time was 3.8 (interquartile range 3.2-4.0) years. A total of 8922 cases of ESRD and 46 032 deaths occurred during 664 446 person-years of observation. Among HIV-infected patients, there were 121 deaths and 102 cases of ESRD over 1536 person-years of observation ( Table 2 ). The majority of these cases (66 deaths and 85 cases of ESRD) occurred among black patients. Among patients with diabetes, there were 5991 cases of ESRD and 22 094 deaths during 272 847 person-years of follow-up.
Death
Mortality rates were much higher among patients with HIV compared with all other groups ( Table 2) . Among black patients, the age-and sex-adjusted mortality rate (per 1000 person-years) among HIV-infected individuals, 120.5 (confidence interval (CI) 90.9-150.1), was approximately double the rate found among those with diabetes, 60.4 (CI 57.4-63.4). Among white patients, the age-and sex-adjusted 
ESRD
The age-and sex-adjusted incidence rates of ESRD per 1000 person-years were similar between black patients with HIV and diabetes, 71.1 (95% CI 55.4-86.7) versus 59.9 (CI 56.7-63.1), as shown in Table 2 . Rates in these groups were higher than those among black patients with neither condition (27.9, CI 25.7-30.1). In contrast, among white patients, the age-and sex-adjusted incidence of ESRD per 1000 person-years was much lower in patients with HIV, 11.3 (CI 5.9-16.6), than patients with diabetes, 22.0 (CI 21.2-22.8), and similar to the rate among patients with neither condition, 7.8 (CI 7.5-8.3). In multivariate Cox proportional hazard analysis, both HIV (HR 2.11, CI 1.46-3.06) and diabetes (HR 1.78, CI 1.63-1.93) were strongly associated with ESRD among black patients when compared with the referent group with neither condition. Among white patients, diabetes doubled the risk of ESRD (HR 1.97, CI 1.86-2.08), but HIV was not associated with an increased risk of ESRD (HR 0.68, CI 0.26-1.76). Among cohort members with age o65 years, the adjusted HR for ESRD was 2.08 (CI 1.44-3.00) for black patients with HIV and 1.88 (CI 1.67-2.12) for black patients with diabetes.
Mean annual change in eGFR
Point estimates for rates of eGFR decline were greatest among black patients with HIV compared with other groups throughout the range of baseline eGFR (Table 3) ; however, There were 170 patients who had both HIV and diabetes and contributed to event rates for both groups. The multivariate hazard ratio for ESRD and death utilize interaction terms to exclude the effect of overlap between diagnoses and isolate the individual effect of HIV and diabetes, respectively.
b Adjusted for age, race, sex, baseline estimated glomerular filtration rate, hypertension, coronary artery disease, heart failure, chronic obstructive lung disease, peripheral vascular disease, hepatitis C infection, cerebrovascular disease, and socioeconomic status. ). Among black patients o65 years, overall rates of eGFR change per year were À4.8 (CI À7.4, À2.2) for HIV-infected patients and À2.4 (CI À2.8, À1.9) for patients with diabetes.
DISCUSSION
In this large, national sample of veterans with CKD, we found that the impact of HIV on rates of death, ESRD, and kidney function decline differed significantly by white/black race. HIV was a strong risk factor for mortality in both white and black patients with CKD, however, black individuals with HIV had higher rates of death, ESRD and renal function decline when compared with their white counterparts. Furthermore, black individuals with HIV had higher rates of death, and similar rates of ESRD and renal function decline compared with the high-risk group of black patients with diabetes. In contrast, among HIV-infected white individuals with CKD, we observed relatively high mortality rates, but a low incidence of ESRD, and modest rates of eGFR decline. Our results highlight the need to investigate mechanisms for ESRD and death in the HIV-infected population and reasons for racial differences in outcomes.
Prior studies have supported the association between CKD and mortality among HIV-infected individuals. In the HIV Epidemiology Research Study (HERS), among 885 HIVinfected women, renal abnormalities at baseline (defined as proteinuria or an increased creatinine 41.4 mg/dl) were associated with an adjusted HR of 2.5 (1.9-3.3) for mortality. 11 Extending these results, an analysis from the Women's Interagency HIV Study (WIHS) found that the presence of proteinuria and elevated serum creatinine level was independently associated with an increased risk of death among HIV-infected women. 10 These studies examined a total of approximately 350 women with kidney disease at baseline and did not analyze progression to ESRD, rates of kidney function decline, or provide comparisons with HIVnegative groups. Case series of HIV-infected individuals with CKD have also established high-mortality rates in this patient group. However, these studies were limited to patients who were evaluated by kidney biopsy, and were conducted before the advent of antiretroviral therapy. 3, [6] [7] [8] [9] Our study builds on these findings by examining the impact of HIV in the context of a large, predominantly male, contemporary patient population with CKD. Three significant clinical outcomes, including death, ESRD, and rates of eGFR decline were analyzed, providing a broad, inclusive view of the clinical implications of CKD among HIV-infected individuals. In addition, the use of HIVnegative controls in this study allows comparison with established risk factors for ESRD such as diabetes, and illustrates areas where the care for HIV-infected patients with CKD could be improved. Finally, the large number of patients with CKD allows a detailed characterization of the interaction between CKD and race.
Prior studies have recognized that CKD is an independent risk factor for mortality in the general population. 12, 13 In our study, even within the context of this high risk group, both white and black patients with HIV had increased mortality when compared with other disease states, such as diabetes. It is unclear why mortality in the setting of CKD should be magnified by HIV infection. In general, increased mortality among CKD patients has been attributed to cardiovascular disease, 12, 14 prompting recommendations for cardiovascular risk reduction as part of CKD management. 15 In this cohort, the relatively low prevalence of cardiovascular disease among patients with HIV suggests that alternative mechanisms of mortality may be relevant to the HIV-infected CKD population. Although, some studies have found that cardiovascular disease is increased in the setting of HIVinfection compared with HIV-negative controls, 16 ,17 mortality rates in HIV-infected individuals included in kidney biopsy studies appear to correlate with the severity of HIV infection. 9, 18, 19 Among HIV-infected women in the HERS cohort, HIV or AIDS-related causes were recorded on death certificates of 58% of patients with elevated creatinine or proteinuria. Data from the WIHS cohort suggest that elevated serum creatinine levels are a predictor for the development of the acquired immune deficiency syndrome (AIDS). 10 Collectively, these observations raise the question of whether the optimal approach to reducing mortality in HIV-infected individuals with CKD differs from the strategy used in the HIV-negative population. Further studies are needed to elucidate mechanisms for increased death in this group in the present era of antiretroviral therapy and to determine whether interventions focused on virologic suppression can improve CKD outcomes.
Although both black and white HIV-infected patients in this cohort had higher death rates than their counterparts with diabetes, black patients also had much higher rates of progression to ESRD and experienced a faster mean decline in eGFR than white patients with HIV. Rates of ESRD among black patients with HIV were similar to those in the high-risk group of black patients with diabetes. These findings are consistent with the known overrepresentation of black patients in the United States Renal Data System dialysis registry 1, 20, 21 and in renal biopsy series conducted in HIVinfected patients. 6, 9, 19, 22, 23 In addition, black race is known to be a risk factor for the development of CKD among HIVinfected persons. 3, 24 Although the racial predilection of kidney disease among HIV-infected individuals has been established, the magnitude of these differences in comparison with other high risk groups, such as those with diabetes, had previously not been well characterized. Collectively, these findings raise the question of whether the optimal approach to CKD management among HIV-infected individuals may differ according to the race of the patient. Among black individuals, early identification of CKD and interventions to slow progression of renal disease are of paramount importance. Among white patients, particularly those with only moderate reductions in eGFR, interventions focused on mortality reduction may have a greater benefit than those directed at slowing progression of renal disease. Perhaps most importantly, these striking racial differences in CKD progression among patients with HIV highlight the critical need for studies devoted to the understanding of underlying disease mechanisms for HIV-related renal disease.
The strengths of our study include its large sample size, national scope, and the availability of high-quality outcome data on death and ESRD. Our study also has several limitations, which are primarily related to the use of 'real world' clinical data obtained as part of routine clinical care and obtained in a single health care system. Specifically, the cohort was limited to patients who met criteria for CKD based on having two eGFR measurements at least 3 months apart. Our sample thus excluded patients who may have had CKD but did not undergo the requisite number and spacing of creatinine measurements required for cohort entry. Although this limitation is unlikely to impact our primary finding of race differences in outcomes among patients with HIV and CKD, it may have resulted in inflated rates of ESRD among cohort members.
Use of the Modification of Diet in Renal Disease (MDRD) equation to estimate GFR has several limitations. This equation may be inaccurate in the clinical setting, where creatinine measurements are not typically calibrated the MDRD laboratory at the Cleveland Clinic. 25 In addition, the MDRD equation has not been independently validated as a measure of GFR among HIV-infected persons. It is possible that systematic differences in the accuracy of the MDRD equations among patients with and without HIV may contribute to the observed differences in outcomes. Nevertheless, the prognostic significance of eGFR among patients with HIV reported here is highly relevant to clinical practice. Estimation of GFR using the MDRD equation has been widely incorporated into routine clinical care and this method is specifically recommended by current Infectious Disease Society of America Guidelines for assessment of kidney function in the HIV-infected population. 4, 15 Our study included a national sample of predominantly male patients who were insured and received care in the Department of Veterans Affairs (VA) health-care system. Results may not be generalizable to uninsured patients, nonveteran populations, women, or other race/ethnic groups not studied here. Previous studies have shown that veterans receiving care at the VA have a higher prevalence of comorbidity when compared with non-veterans in both diabetic and non-diabetic populations. 26, 27 However, HIVinfected veterans receiving care in the VA appear to have less AIDS-defining conditions and higher CD4 þ counts than non-veterans. 28 Therefore, relative differences in CKD outcomes between HIV-infected and diabetic populations may be conservative estimates when compared with settings outside of the VA health-care system. It should also be noted that although the gender composition of the veteran population studied here is mostly male, approximately 80% of HIV-infected persons in the United States are also male. 29 Overall rates of change in eGFR per year in this cohort were relatively low. [30] [31] [32] [33] Low rates of eGFR decline may be in part reflect our study design: we excluded creatinine measurements within 90 days of death or ESRD and patients with an eGFR o15 ml/min/1.73 m 2 at baseline; we included only patients receiving outpatient care and had undergone at least two creatinine measurements at least 3 months apart (i.e. those who were likely to have their kidney disease actively managed by a physician). It is also possible that low observed rates of eGFR decline may reflect the advanced age of the group studied. Repeated measures analysis may also be prone to regression to the mean, which may cause rates to appear lower than expected. 34, 35 Despite adjusting our analyses for a large number of comorbid conditions and sociodemographic characteristics, the possibility of residual confounding by factors not included in the analysis (e.g. proteinuria, body mass index, diet) or by differences in disease severity (e.g. stage of heart failure or severity of diabetes) that could not be defined by the data sources available to us cannot be ruled out. We also relied on ICD-9 codes to identify patients with diabetes, which may have lead to some patients being misclassified. However, it is reassuring that incidence rates for ESRD and mortality are of similar magnitude with previously published estimates.
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CONCLUSION
HIV-infection has important clinical implications among patients with CKD. Although HIV is a strong risk factor for mortality in both white and black CKD patients, rates of death, ESRD, and renal function decline differ greatly between HIV-infected patients of white or black race. These differences raise the question of whether race should be a consideration in the management of patients with HIV and CKD and highlight the importance of future investigations into causes of death and mechanisms underlying progression of kidney disease in this population.
MATERIALS AND METHODS Patients
Our goal was to identify a cohort of patients who fulfilled the National Kidney Foundation definition for CKD stage 3 or higher. 15 A total of 2 352 584 veterans age 18-100 years had at least one outpatient serum creatinine measured at a Department of VA facility between October 1, 2000 and September 30, 2001 . Among these patients, 11 125 who had already reached ESRD (defined as receipt of chronic dialysis or kidney transplant) were excluded. Next, eGFR was calculated using the abbreviated MDRD formula based on age, sex, race, and serum creatinine. There were 1 897 758 patients with an eGFR X60 ml/min/1.73 m 2 who were eliminated. 39, 40 From the remaining group (n ¼ 445 108), there were 209 622 patients who had an eGFR o60 ml/min/1.73 m 2 for at least 3 months prior based on a second outpatient serum creatinine measurement. Each patient's date of first creatinine measurement between October 1, 2000 and September 30, 2001 was used as the point of cohort entry. There were 4701 (2.2%) patients in whom race was unknown and 1994 (1.0%) patients who were neither white nor black. These patients were excluded, leaving an analytic cohort of 202 927 patients.
Data sources
The data sources used to assemble the study cohort have been described in detail previously. 41 The VA Decision Support System Laboratory Results file provided serum creatinine measurements associated with outpatient visits. 42 The Immunology Case Registry (ICR) was used to identify all patients with HIV. 43 The ICR is a national VA administrative database designed to monitor healthcare utilization among all of its HIV-infected patients. The ICR, VA National Patient Care Database, Fee Basis files, and inpatient and outpatient Medicare claims were used to ascertain demographic and comorbidity information. 44, 45 When available, race information from the Medicare denominator file was used preferentially based on its superior reliability to VA race data. 46 Since 2003, the VA adopted a new system of race reporting to conform with federal guidelines and in doing so, established 95% agreement between observer reported data with self-reported race. 47 Overall, 95.6% (n ¼ 193 966) of patients in our cohort had race characterized by Medicare or updated VA data sources. Patients treated with chronic dialysis or kidney transplant were identified using the United States Renal Data System, a comprehensive national ESRD registry. 48 Date of death information for cohort members was provided by the VA Beneficiary Identification and Records Locator Subsystem. [49] [50] [51] Area-level socioeconomic data were obtained by matching an individual's residential zip code to year 2000 United States Census zip code tabulation areas. 52 
Outcomes
The outcomes for our study included time from cohort entry to: (1) onset of ESRD (defined as initiation of chronic dialysis or kidney transplantation) or (2) death through September 30, 2004 . Patients were censored at the time of the first occurrence of death, ESRD, or September 30, 2004 . In a supplementary analysis, mean annual rates of eGFR change were calculated based on serial serum creatinine measurements available during follow-up.
Primary predictors
The primary predictor for our analysis was the presence of HIV infection. Patients with HIV were identified by matching our cohort to the ICR. We considered only patients that entered the ICR before the time of cohort entry. A diagnosis of HIV was confirmed before the time of cohort entry based on previous treatment with antiretroviral therapy or the Centers for Disease Control and Prevention (CDC) case definition. 53 Diabetes status was designated using methods validated for VA administrative databases based on information entered between January 1, 1999 and the time of cohort entry. 54 Patients without HIV or diabetes served as the referent group for evaluating the relative hazard of ESRD and death.
Covariates
In multivariate models, analyses were adjusted for age, sex, and the following diagnosed conditions based on International Classification of Diseases, ninth Revision (ICD-9) and Current Procedural Terminology codes: coronary artery disease (defined as a prior diagnosis of coronary artery disease, angina, or myocardial infarction or prior coronary artery bypass graft or angioplasty), congestive heart failure, hypertension, peripheral arterial disease (defined as a prior diagnosis of peripheral arterial disease or prior lower extremity amputation or revascularization procedure), chronic obstructive pulmonary disease, cerebrovascular disease (defined as prior stroke or transient ischemic attack), and hepatitis C virus infection status. 41 All analyses were stratified by white/black race to accommodate a race interaction. We also adjusted for eGFR at the time of cohort entry. Socioeconomic status was classified using area-level socioeconomic factors derived from US Census data: median household income, median value of housing units, percentage of residents older than 25 years who are high school graduates, percentage of residents older than 25 years with a bachelor's degree, number of residents in executive, managerial, or professional specialty occupations, number of families below the poverty level, and number of housing units occupied by the owner. Using a technique reported previously for census blocks, we calculated a z-score for each zipcode by subtracting the mean value for the variable and dividing by the standard deviation. 55 Overall summary scores for socioeconomic status were derived for each patient by summing z-scores for each socioeconomic variable. Patients were then divided into tertiles according to summary socioeconomic scores. Socioeconomic information was not available due to missing zip code information in o0.1% of patients (n ¼ 9) and because zip codes could not be linked to a zip code tabulation area in the US census in 2.4% of patients (n ¼ 4.938). For patients with missing information on zip code socioeconomic status, a missing indicator variable for socioeconomic status was included in multivariate analysis.
Statistical analyses
Baseline characteristics were compared among cohort patients with HIV, diabetes, and patients without either of these conditions using the w 2 test for categorical variables and the ANOVA test for comparison of means for continuous variables. Age-and sexadjusted incidence rates for ESRD and death were obtained using a parametric regression survival-time model fitted to the exponential distribution and standardized to the median age of the source population. Cox proportional hazard analysis was used to compare the adjusted association of HIV with time to ESRD and time to death, respectively, with patients without HIV or diabetes serving as the referent group. Interaction terms for HIV and diabetes were utilized to isolate the effect of HIV and diabetes, respectively; that is this allowed us to exclude the effect of having both conditions simultaneously. For these analyses, patients were censored at the time of first occurrence of death, ESRD, or September 30, 2004 . Estimates were adjusted for age, sex, eGFR, baseline comorbidities, and socioeconomic status.
Rates of change in eGFR (ml/min/1.73 m 2 per year) were estimated using a mixed effects linear regression model, which accounted for variations in the number and spacing of creatinine measurements and length of follow-up for each subject. For this analysis, 2908 patients who had already reached renal failure at the time of cohort entry (eGFR o15 ml/min/1.73 m 2 ) were excluded. To avoid analyzing creatinine measurements occurring near the time of death or onset of ESRD (which may not reflect chronic rates of progression), we also excluded 66 104 eGFR measurements that occurred 90 days before ESRD or death. Thus, our analyses were conducted among 196 418 patients who contributed 1 840 815 creatinine measures to our analysis.
A supplementary analysis of these outcomes was performed among the subgroup of patients with age o65 years. All regression models were validated when checked by bootstrap methods and by comparing robust standard errors. For Cox models, the proportional hazards assumption was checked using the Schoenfeld test and by graphically comparing stratified log (Àlog (survivor function)) versus time curves. Assumptions of the mixed effects model were tested and satisfied. Analyses were conducted using Stata version 9.0 (Stata Corp, College Station, TX, USA). This study was approved by the Institutional Review Board at the University of California, San Francisco, and the Research Committee at the VA San Francisco.
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